BioSpace News Archive

Year

• 2005
• 2006
• 2007
• 2008
• 2009
• 2010
• 2011
• 2012
• 2013
• 2014
• 2015
• 2016
• 2017
• 2018
• 2019
• 2020
• 2021
• 2022
• 2023
• 2024
• 2025

Month

• January
• February
• March
• April
• May
• June
• July
• August
• September
• October
• November
• December

Day

• 1
• 2
• 3
• 4
• 7
• 8
• 9
• 10
• 11
• 14
• 15
• 16
• 17
• 18
• 20
• 21
• 22
• 23
• 24
• 25
• 28
• 29
• 30
• 31

• 

  Career Advice

  Back to School? From Industry to Academia

  In a tough labor market where layoffs continue, some are considering—or even moving—from industry to academia, according to a BioSpace poll. A career coach, scientist and general practitioner turned research coordinator share their thoughts.

  October 17, 2024

   · 

  6 min read

   · 

  Angela Gabriel
• 

  Infectious disease

  GSK, ViiV Tout 99% Effectiveness for Long-Acting HIV PrEP as Gilead Gains Ground

  Real-world evidence show that GSK and ViiV Healthcare’s long-acting pre-exposure prophylaxis Apretude can prevent nearly all HIV infections, while rival Gilead Sciences is moving quickly toward an approval for a twice-yearly option.

  October 17, 2024

   · 

  2 min read

   · 

  Tristan Manalac
• 

  Drug Development

  Kezar Cuts Lupus Program After Patient Deaths, Focuses on Autoimmune Hepatitis

  Earlier this month, Kezar Life Sciences announced that the mid-stage test of zetomipzomib in lupus nephritis had been placed on an FDA clinical hold. Now, that program is being terminated.

  October 17, 2024

   · 

  2 min read

   · 

  Annalee Armstrong
• 

  Vaccines

  Bavarian Nordic’s Jynneos Elicits ‘Robust’ Mpox Antibody Response in Adolescents: Study

  The mpox vaccine induced an antibody response in adolescents aged 12 to 17 years that matched that in adults, suggesting the shot can be used to protect the highly susceptible group.

  October 17, 2024

   · 

  2 min read

   · 

  Tristan Manalac
• 

  Radiopharmaceuticals

  Sanofi Inks $326M Radiopharma Deal With Orano

  Thursday’s agreement with Orano Med is the second in as many months. Sanofi in September made its first foray into the radioligand space with a $110 million licensing deal with Orano Med and Texas biotech RadioMedix.

  October 17, 2024

   · 

  2 min read

   · 

  Tristan Manalac
• 

  Lymphoma

  BMS’ Opdivo Bests Pfizer’s Adcetris in Late-Stage Hodgkin’s Lymphoma Study

  Opdivo showed a 52% progression-free survival advantage over Adcetris in newly diagnosed Hodgkin’s lymphoma, according to a Phase III study that combined either therapy with doxorubicin, vinblastine and dacarbazine.

  October 17, 2024

   · 

  2 min read

   · 

  Tristan Manalac
• 

  Layoffs

  Sage Therapeutics Will Lay Off 33% of Employees, Including Over Half of R&D

  As part of a strategic reorganization intended in part to support the ongoing launch of its postpartum depression drug, Sage Therapeutics is cutting more than 165 employees.

  October 17, 2024

   · 

  2 min read

   · 

  Angela Gabriel
• Press Releases

  Wave Life Sciences Announces Upcoming Virtual Research Day on Wednesday, October 30, 2024

  October 17, 2024

   · 

  2 min read
• Press Releases

  Adverum Biotechnologies Appoints Jason L. Mitchell as Chief Commercial Officer as it Prepares to Initiate Pivotal Program

  October 17, 2024

   · 

  6 min read
• Press Releases

  Tonix Pharmaceuticals Announces Submission of the TNX-102 SL New Drug Application (NDA) for Fibromyalgia to the U.S. Food and Drug Administration (FDA)

  October 17, 2024

   · 

  11 min read